Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  JIM - Journal of Immunological Methods

• Publication date

  1991-02-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0022-1759(91)90009-5PMID 1705571
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies

  1990cited by this paper
• Regulation of human B-cell ontogeny.

  1990cited by this paper
• The effects of aromatic and aliphatic maleimide crosslinkers on anti-CD5 ricin immunotoxins.

  1989cited by this paper
• Efficient endotoxin removal with a new sanitizable affinity column: Affi-Prep Polymyxin.

  1989cited by this paper
• Detailed Studies on Expression and Function of CD19 Surface Determinant by Using B43 Monoclonal Antibody and the Clinical Potential of Anti-CD19 Immunotoxins

  1988cited by this paper
• Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD19.

  1988cited by this paper
• Large scale preparation of immunotoxins constructed with the Fab' fragment of IgG1 murine monoclonal antibodies and chemically deglycosylated ricin A chain.

  1988cited by this paper
• IMMUNOTOXINS FOR EX VIVO MARROW PURGING IN AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR ACUTE NONLYMPHOCYTIC LEUKEMIA

  1988cited by this paper
• Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.

  1988cited by this paper
• Immunobiologic differences between normal and leukemic human B-cell precursors.

  1988cited by this paper
• Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia.

  1987cited by this paper
• Redesigning nature's poisons to create anti-tumor reagents.

  1987cited by this paper
• Immunotoxins.

  1986cited by this paper
• Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia

  1986cited by this paper
• Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein.

  1985cited by this paper
• Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow.

  1985cited by this paper
• Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation.

  1985cited by this paper
• Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins.

  1985cited by this paper
• Ricin-like plant toxins are evolutionarily related to single-chain ribosome-inhibiting proteins from Phytolacca.

  1984cited by this paper
• Seasonal variations in different forms of pokeweed antiviral protein, a potent inactivator of ribosomes.

  1983cited by this paper
• Pokeweed antiviral protein.

  1983cited by this paper
• High-sensitivity sequencing with a gas-phase sequenator.

  1983cited by this paper
• Kinetics of protein synthesis inactivation by ricin-anti-Thy 1.1 monoclonal antibody hybrids. Role of the ricin B subunit demonstrated by reconstitution.

  1982cited by this paper
• The Preparation and Cytotoxic Properties of Antibody‐Toxin Conjugates

  1982cited by this paper
• Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins.

  1981cited by this paper
• An efficient mRNA-dependent translation system from reticulocyte lysates.

  1976cited by this paper
• Purification and partial characterization of the antiviral protein from Phytolacca americana which inhibits eukaryotic protein synthesis.

  1975cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• A protein sequenator.

  1967cited by this paper

• Plant-made immunotoxin building blocks: A roadmap for producing therapeutic antibody-toxin fusions.

  2020cites this paper
• The future of antiviral immunotoxins

  2016cites this paper
• Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children’s Oncology Group

  2015cites this paper
• Pokeweed Antiviral Protein, a Ribosome Inactivating Protein: Activity, Inhibition and Prospects

  2015cites this paper
• Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy

  2014cites this paper
• Classic Immunotoxins with Plant or Microbial Toxins

  2013cites this paper
• (anti-CD19)- pokeweed antiviral protein immunotoxin in mice with severe combined immunodeficiency using B43 Biotherapy for xenografted human central nervous system leukemia

  2011cites this paper
• The characterisation of a recombinant cytosolic shuttle based on ricin toxin

  2011cites this paper
• X‐ray crystallographic analysis of the structural basis for the interaction of pokeweed antiviral protein with guanine residues of ribosomal RNA

  2008cites this paper
• Immunotoxin Using Anti-CD 19 ( B 43 )-Pokeweed Antiviral Protein Combined Immunodeficient Mice and Successful Treatment Establishment of a Human t ( 4 ; 11 ) Leukemia in Severe Updated

  2006cites this paper
• Immunotoxins in the treatment of hematologic malignancies.

  2006cites this paper
• EFFECT OF POKEWEED ANTIVIRAL PROTEIN IN COMBINATION WITH GUANIDINE ON POLIOVIRUS MACROMOLECULAR SYNTHESIS

  2006cites this paper
• In Vitro and in Vivo Cytotoxicity of an Anti-Osteosarcoma Immunotoxin Containing Pokeweed Antiviral Protein 1

  2006cites this paper
• CNS activity of Pokeweed Anti-viral Protein (PAP) in mice infected with Lymphocytic Choriomeningitis Virus (LCMV)

  2005cites this paper
• Comparative evaluation of two purification methods of anti-CD19-c-myc-His6-Cys scFv.

  2005cites this paper
• Mucosal Toxicity Studies of a Gel Formulation of Native Pokeweed Antiviral Protein

  2004cites this paper
• Binding and Cytotoxicity of Conjugated and Recombinant Fusion Proteins Targeted to the Gonadotropin-Releasing Hormone Receptor

  2004cites this paper
• A 13-week subchronic intravaginal toxicity study of pokeweed antiviral protein in mice.

  2004cites this paper
• High resolution X-ray structure of potent anti-HIV pokeweed antiviral protein-III.

  2003cites this paper
• Cytotoxic activity of gonadotropin-releasing hormone (GnRH)-pokeweed antiviral protein conjugates in cell lines expressing GnRH receptors.

  2003cites this paper
• Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma

  2001cites this paper
• Chemical construction of immunotoxins

  2001cites this paper
• Pokeweed antiviral protein: a potential nonspermicidal prophylactic antiviral agent.

  2001cites this paper
• X-ray crystallographic analysis of pokeweed antiviral protein-II after reductive methylation of lysine residues.

  2000cites this paper
• Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia.

  1999cites this paper
• X‐ray crystallographic analysis of the structural basis for the interactions of pokeweed antiviral protein with its active site inhibitor and ribosomal RNA substrate analogs

  1999cites this paper
• Pokeweed antiviral protein and its applications.

  1999cites this paper
• High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.

  1999cites this paper
• Pokeweed antiviral protein isoforms PAP-I, PAP-II, and PAP-III depurinate RNA of human immunodeficiency virus (HIV)-1.

  1999cites this paper
• A requirement for protein kinase C inhibition for calcium-triggered apoptosis in acute lymphoblastic leukemia cells.

  1999cites this paper
• Mouse Monoclonal Antibodies against Phytolacca americana Antiviral Protein PAP I

  1999cites this paper
• Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.

  1998cites this paper
• Effective adoptive immunotherapy by T-LAK cells retargeted with bacterial superantigen-conjugated antibody to MUC1 in xenografted severe combined immunodeficient mice.

  1998cites this paper
• The low expression level of pokeweed antiviral protein (PAP) gene in Escherichia coli by the inducible lac promoter is due to inefficient transcription and translation and not to the toxicity of the PAP.

  1998cites this paper
• Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia.

  1998cites this paper
• Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.

  1998cites this paper
• Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.

  1997cites this paper
• Large scale manufacturing of TXU(anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate for clinical trials.

  1997cites this paper
• Immunotoxins for the Treatment of B-Cell Lymphomas

  1997cites this paper
• Expression and activity of a recombinant chimeric protein composed of pokeweed antiviral protein and of human interleukin‐2

  1997cites this paper
• Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.

  1997cites this paper
• Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.

  1996cites this paper
• Immunotoxins: an update.

  1996cites this paper
• Signal Transduction through the 1 Integrin Family Surface Adhesion Molecules VLA-4 and VLA-5 of Human B-cell Precursors Activates CD19 Receptor-associated Protein-tyrosine Kinases (*)

  1996cites this paper
• Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.

  1996cites this paper
• Production and characterization of monoclonal antibodies against the ribosome-inactivating protein PAP from Phytolacca americana.

  1995cites this paper
• Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.

  1995cites this paper
• In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein.

  1995cites this paper
• Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule.

  1995cites this paper
• An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.

  1995cites this paper
• Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen.

  1995cites this paper
• In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells.

  1995cites this paper
• Isolation and characterization of a cDNA clone encoding the pokeweed antiviral protein II from Phytolacca americana and its expression in E. coli

  1994cites this paper
• Phytolacca americana L. (Pokeweed): In Vitro Production of Betacyanins and Medicinal Compounds

  1994cites this paper
• Immunotoxins in the therapy of cancer: from bench to clinic.

  1994cites this paper
• Immunotoxins against cancer.

  1994cites this paper
• Ribosome-inactivating proteins from plants.

  1993cites this paper
• Immunotoxins: magic bullets or misguided missiles?

  1993cites this paper
• Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny.

  1993cites this paper
• Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.

  1993cites this paper
• Toxin-targeted design for anticancer therapy. II: Preparation and biological comparison of different chemically linked gelonin-antibody conjugates.

  1993cites this paper
• Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein

  1993cites this paper
• Mutations dissociating the inhibitory activity of the pokeweed antiviral protein on eukaryote translation and Escherichia coli growth.

  1993cites this paper
• In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.

  1993cites this paper
• Immunotoxins: magic bullets or misguided missiles?

  1993cites this paper
• Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.

  1993cites this paper
• Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.

  1993cites this paper
• Pokeweed antiviral protein: ribosome inactivation and therapeutic applications.

  1992cites this paper
• Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43)-pokeweed antiviral protein immunotoxin.

  1992cites this paper
• In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia

  1992cites this paper
• Production and Characterization of a Monoclonal Antibody Against the Ribosome Inactivating Protein Alpha Sarcin

  1992cites this paper
• In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.

  1992cites this paper
• Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.

  1992cites this paper
• G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells.

  1992cites this paper
• Effect of Pokeweed Antiviral Protein in Combination with Guanidine on Poliovirus Macromolecular Synthesis

  1992cites this paper
• Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.

  1992cites this paper
• Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein

  1992cites this paper
• In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.

  1992cites this paper
• Minlreview Immunotoxins for the Treatment of B-Cell Lymphomas

  year unknowncites this paper